Latest News

Remdesivir Plus Dexamethasone Reduces Mortality Risk among Adults Hospitalized with COVID-19
Remdesivir Plus Dexamethasone Reduces Mortality Risk among Adults Hospitalized with COVID-19

October 10th 2024

Remdesivir plus dexamethasone was associated with reduced 14- and 28-day mortality vs dexamethasone alone, according to a large study of adults hospitalized with COVID-19.

COVID-19 Linked to Long-Term Risk of MACE, Especially Among Adults with non-O Blood Types
COVID-19 Linked to Long-Term Risk of MACE, Especially Among Adults with non-O Blood Types

October 9th 2024

FDA Grants Marketing Authorization to First OTC Flu/COVID-19 Test Outside Emergency Use Declaration/ image credit - FDA logo: ©Araki Ilustrations/stock.adobe.com
FDA Grants Marketing Authorization to First OTC Flu/COVID-19 Test Outside Emergency Use Declaration

October 8th 2024

US Pertussis Cases Increase Nearly 5-Fold During 2024, According to the CDC / image credit - CDC logo: ©Tada Images/stock.adobe.com
US Pertussis Cases Increase Nearly 5-Fold During 2024, According to the CDC

October 2nd 2024

RSV Mortality Higher than for Influenza B 90 Days After Hospital Discharge: New Data / image credit - flu and rsv viruses: ©Kateryna_Kon/stock.adobe.com
RSV Mortality Higher than for Influenza B 90 Days After Hospital Discharge: New Data

October 1st 2024

More News

© 2024 MJH Life Sciences

All rights reserved.